SynthesisDeutsches Arzteblatt international2013
The diagnosis and treatment of giant cell arteritis.
Synthesis in Deutsches Arzteblatt international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Atypical Signs and Symptoms of Giant Cell Arteritis: A Systematic Review.Journal of general internal medicine · 2025Pooled it
- Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis.The Cochrane database of systematic reviews · 2024Pooled it
- [Guidelines from the DOG, RG and BVA: retinal artery occlusion : November 2016 status].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Guideline
- Polymorphism of VEGF gene in susceptibility to chronic immune-mediated inflammatory diseases: a meta-analysis.Rheumatology international · 2015Pooled it
- Orofacial symptoms and diagnostic pathways in patients with giant cell arteritis (GCA): a retrospective case series from a dental perspective.BMC oral health · 2026Article
- Measurement of the impact of giant cell arteritis and treatment with glucocorticoids on health-related quality of life.Therapeutic advances in musculoskeletal disease · 2026Review
- Nocardia farcinica Brain Abscess in a Glucocorticoid-Treated Patient with Giant-Cell Arteritis: A Case Report.The American journal of case reports · 2025Article
- [Anterior ischemic optic neuropathy (AION) : S1 guidelines of the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Version: 30.08.2024].Die Ophthalmologie · 2025Review
- Article
- Review
- Visualization of cranial giant cell arteritis with [Radiology case reports · 2024Article
- Review
- [Nonarteritic anterior ischemic optic neuropathy (nAION)].Die Ophthalmologie · 2023Article
- Questioning the Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Negative Biopsy May Facilitate Decision-making.Plastic and reconstructive surgery. Global open · 2023Article
- Temporal Arteritis Caused by Tertiary Syphilis.Internal medicine (Tokyo, Japan) · 2023Article
- Clinical Features and Outcomes of Japanese Patients with Giant Cell Arteritis: A Comparison with Takayasu Arteritis.Journal of personalized medicine · 2023Article
- Optimizing the use of temporal artery biopsy: a retrospective study.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2023Article
- Case report: Rapid development of amyloid A amyloidosis in temporal arteritis withFrontiers in immunology · 2023Article
- Biopsy-Proven Giant Cell Arteritis Associated Vision Loss in Chinese Subjects: A Case Series and Review of the Literature.Neuro-ophthalmology (Aeolus Press) · 2023Article
- Temporal Artery Biopsy Debate: Positive TAB Result Prolongs Steroid Use in Giant Cell Arteritis.Plastic and reconstructive surgery. Global open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell arteritis (GCA) is the most common systemic vasculitis in persons aged 50 and above (incidence, 3.5 per 100,000 per year). It affects cranial arteries, the aorta, and arteries elsewhere in the body, e.g., in the limbs.
methodsWe selectively review the pertinent literature, including guidelines and recommendations from Germany and abroad.
resultsThe typical symptoms of new-onset GCA are bitemporal headaches, jaw claudiacation, scalp tenderness, visual disturbances, systemic symptoms such as fever and weight loss, and polymyalgia. The diagnostic assessment comprises laboratory testing (erythrocyte sedimentation rate, C-reactive protein), imaging studies (duplex sonography, high-resolution magnetic resonance imaging, positron-emission tomography), and temporal artery biopsy. The standard treatment is with corticosteroids (adverse effects: diabetes mellitus, osteoporosis, cataract, arterial hypertension). A meta-analysis of three randomized controlled trials led to a recommendation for treatment with methotrexate to lower the recurrence rate and spare steroids. Patients for whom methotrexate is contraindicated or who cannot tolerate the drug can be treated with azathioprine instead.
conclusionGiant cell arteritis, if untreated, progresses to involve the aorta and its collateral branches, leading to various complications. Late diagnosis and treatment can have serious consequences, including irreversible loss of visual function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.